Additional members of the ACTG New Work Concept Sheet 273 team included: Mariana Gerschenson (University of Hawaii-Manoa), Justin McArthur (Johns Hopkins University), and David Simpson (Mount Sinai University).
The authors gratefully acknowledge the many HIV-infected patients who participated in ACTG study 384 and protocol A5128. We also acknowledge Laura Smeaton (Harvard School of Public Health), for invaluable assistance with clinical data from ACTG study 384, and Melanie Robinson in the Vanderbilt Microarray Shared Resource Core Facility.
Additional members of the ACTG 384 study leadership team included: Victor De Gruttola (Harvard School of Public Health), Sally Snyder, Thomas Nevin (Social & Scientific Systems), Carla Pettinelli (National Institutes of Health), Michael Dube (Indiana University), Margaret Fischl (Miami University), Richard Pollard (Univ. California-Davis), Robert Delaphna (Howard University), Linda Gideon (Frontier Science and Technology Foundation), Charles van der Horst (Univ. of North Carolin-Chapel Hill), Robert Murphy (Northwestern University), Mark Becker (Agouron), Richard D’Aquila (Vanderbilt University), Stefano Vella (Istituto Superiore de Sanita), Thomas Merigan (Stanford University) and Martin Hirsch (Harvard Medical School).
Other members of the ACTG 384 team were M. Nokta (University of Texas, Galveston), V. Johnson (University of Alabama, Birmingham), G. Morse (State University of New York, Buffalo), B. Putnam (University of Colorado), M. Klebert (Washington University), A. Martinez (National Institutes of Health), A. Chiesi, C. Tomino (Istituto Superiore de Sanita), S. Deeks (University of California, San Francisco), M. Testa (Harvard School of Public Health), T. Nevin (Social & Scientific Systems), J. Levin, V. French, O. Fennell (Adult AIDS Clinical Trials Group Community Constituency Group), M. Stevens, R. Grosso, B. Dusak, S. Hodder, M. Swingle (Bristol-Myers Squibb), C. Brothers, J. Tolson (GlaxoSmithKline), R. Leavitt (Merck), D. Manion, N. Ruiz, K. Morrissey (DuPont Pharmaceuticals), B. Quart (Agouron), C. Jennings (Northwestern University), S. Dascomb, M. Cooper, M. Murphy, K. Blakelock (Frontier Science and Technology Foundation), A. Doolan (Massachusetts General Hospital).
Funding for the genomic sequencing and analyses was provided by the National Institutes of Health (NIH)/National Institute of Neurological Diseases and Stroke grant NS059330. The project described was also supported by Award Number U01AI068636 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. AIDS Clinical Trials Group (ACTG) Study 384 was also supported by grant AI38858, and by Agouron/Pfizer, Bristol Myers Squibb, and GlaxoSmithKline. The ACTG sites contributing DNA for these analyses were funded by NIH grants AI069513, AI34835, AI069432, AI069423, AI069477, AI069501, AI069474, AI069428, AI69467, AI069415, Al32782, AI27661, AI25859, AI069495, AI069471, AI069532, AI069452, AI069450, AI069556, AI069484, AI069472, AI34853, AI069465, AI069511, AI38844, AI069424, AI069434, AI46370, AI069502, and AI069419. The ACTG Human DNA Repository is also supported by NIH grant RR024975. Additional NIH grant support included: AI077505, AI54999, MH071205, HL087726, AI69495, and AI062435.
G.K.R. has received research support from Gilead Sciences, Schering-Plough, and served as a consultant for Abbott Laboratories, Boehringer-Ingelheim, and Tibotec.
D.B.C. has received research grants from Pfizer, Schering Plough, Bavarian Nordic, NeurogesX, GlaxoSmithKline, Tibotec, Boehringer-Ingelheim, Gilead, and Biogen, and has served on Scientific Advisory Boards or as a consultant for Biogen, Elan, Roche, Forest Labs, Genentech, GlaxoSmithKline, Millennium Consulting, Schering Plough, Bristol-Meyers Squibb, and Genzyme.
D.W.H. has received research grants from Bavarian Nordic, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck, Tanox, and Tibotec, and has served on Scientific Advisory Boards for Glaxo Smith Kline and Tibotec.
T.H. has received research funding from Merck.